XML 35 R28.htm IDEA: XBRL DOCUMENT v3.21.4

SHARE EXCHANGE AND ASSIGNMENT (Narrative) (Details) - PsilocybinLabs Ltd [Member]	Aug. 07, 2019 CAD ($) Shares shares	Apr. 25, 2019 CAD ($) shares
Share Exchange And Assignment [Line Items]
Number of shares issued by PL to individual | shares		100,000
Value of common stock issued by PL to individual | $		$ 2,000
Common shares purchased | shares	100,000
Number of shares issued | Shares	100,000
Value of common stock shares issued | $	$ 2,000

X

- Definition

Represents the number of common stock shares purchased.

+ References

No definition available.

+ Details

Name:	drug_CommonStockSharesPurchased
Namespace Prefix:	drug_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents the number of shares issued by related party.

+ References

No definition available.

+ Details

Name:	drug_NumberOfSharesIssuedByRelatedParty
Namespace Prefix:	drug_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	drug_ShareExchangeAndAssignmentLineItems
Namespace Prefix:	drug_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the value of common stock shares issued by related party.

+ References

No definition available.

+ Details

Name:	drug_ValueOfCommonStockSharesIssuedByRelatedParty
Namespace Prefix:	drug_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph f
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_EquityInterestsOfAcquirer
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph f
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=drug_PsilocybinlabsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: